August 20, 2018 07:20 AM EDT

Harbour BioMed jumps into the crowded PD-1/L1 race, looking to take a Chinese asset global as checkpoint pipeline bulges

Can two Chinese biotechs vault a homegrown PD-L1 agent to frontrunner status in the crowded global checkpoint race?

Harbour BioMed thinks the answer is yes …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline bulges